Authentication of P.G.I. Gragnano pasta by near infrared (NIR) spectroscopy and chemometrics

Pasta is a typical Italian food item obtained by durum wheat semolina/flour well-known and widely consumed all over the world. Since 2013, Gragnano Pasta, a typical aliment produced in a specific area in the South of Italy, has been awarded with the P.G.I. mark, remarking the high value of this product. Due to its peculiarity and its market value, it is important to characterize and authenticate the Gragnano Pasta. Considering this rationale, the present study aims at developing a non-destructive analytical methodology suitable for this goal. Consequently, the possibility of coupling Near Infrared spectroscopy (NIR) with two different classifiers has been tested. In particular, 949 samples of pasta were analysed, and then classified into categories Gragnano and non-Gragnano by Partial Least Squares Discriminant Analysis (PLS-DA) and Soft Independent Modeling of Class Analogies (SIMCA). In order to externally validate models, samples were divided into a training and a test set of 749 and 200 objects, respectively. Both approaches provided excellent results; PLS-DA correctly classified all the Gragnano samples (and it misclassified only 1 object belonging to the other category), while SIMCA analysis (modelling Class Gragnano) led to 96.57% sensitivity and 100% specificity

N-3 fatty acids in patients with multiple cardiovascular risk factors

BACKGROUND: Trials have shown a beneficial effect of n-3 polyunsaturated fatty acids in patients with a previous myocardial infarction or heart failure. We evaluated the potential benefit of such therapy in patients with multiple cardiovascular risk factors or atherosclerotic vascular disease who had not had a myocardial infarction. METHODS: In this double-blind, placebo-controlled clinical trial, we enrolled a cohort of patients who were followed by a network of 860 general practitioners in Italy. Eligible patients were men and women with multiple cardiovascular risk factors or atherosclerotic vascular disease but not myocardial infarction. Patients were randomly assigned to n-3 fatty acids (1 g daily) or placebo (olive oil). The initially specified primary end point was the cumulative rate of death, nonfatal myocardial infarction, and nonfatal stroke. At 1 year, after the event rate was found to be lower than anticipated, the primary end point was revised as time to death from cardiovascular causes or admission to the hospital for cardiovascular causes. RESULTS: Of the 12,513 patients enrolled, 6244 were randomly assigned to n-3 fatty acids and 6269 to placebo. With a median of 5 years of follow-up, the primary end point occurred in 1478 of 12,505 patients included in the analysis (11.8%), of whom 733 of 6239 (11.7%) had received n-3 fatty acids and 745 of 6266 (11.9%) had received placebo (adjusted hazard ratio with n-3 fatty acids, 0.97; 95% confidence interval, 0.88 to 1.08; P=0.58). The same null results were observed for all the secondary end points. CONCLUSIONS: In a large general-practice cohort of patients with multiple cardiovascular risk factors, daily treatment with n-3 fatty acids did not reduce cardiovascular mortality and morbidity. Copyright © 2013 Massachusetts Medical Society